Menopause is a normal life transition — not a disease. But it can significantly affect quality of life for many women, and it comes with health considerations worth understanding. This page walks through what perimenopause and menopause involve, the range of symptoms women experience, and where hormone replacement therapy fits as one of several management options.

The Stages of the Menopause Transition

Perimenopause

Perimenopause begins when ovarian function starts to fluctuate — often in a woman's 40s, sometimes earlier. Hormone levels become less predictable. Periods may become irregular: shorter cycles, longer cycles, heavier or lighter bleeding, or skipped months. Perimenopause typically lasts 4 to 8 years, but can be shorter or longer. During this period, hormone levels swing rather than steadily decline, which is why symptoms can be unpredictable and sometimes more disruptive.

Menopause

Menopause is technically a single point in time — 12 consecutive months without a period (in the absence of other causes). The average age of natural menopause in Canadian women is around 51, though anywhere from 45 to 55 is considered typical.

Postmenopause

After 12 months without periods, you are considered postmenopausal. Hormone levels are now low and relatively stable. Some symptoms (like hot flashes) may continue for years; others may resolve. Long‑term considerations like bone health, cardiovascular health, and genitourinary changes become more relevant.

Premature and Early Menopause

Menopause before age 40 is considered premature; between 40 and 45, early. This can happen due to surgery (removal of ovaries), medical treatments (chemotherapy, radiation), genetic conditions, or autoimmune issues. For premature or early menopause, prescribers commonly consider hormone therapy until at least the typical age of natural menopause.

Common Symptoms of Perimenopause and Menopause

Symptoms vary widely. Some women have minimal symptoms; others have severely disruptive ones. The most common categories:

• Vasomotor symptoms: Hot flashes and night sweats. Sudden waves of heat, often with flushing and sweating. These are the most‑studied symptoms and the ones for which hormone therapy is most clearly effective.
• Sleep disruption: Trouble falling asleep, waking frequently, or non‑restorative sleep. Sometimes driven by night sweats; sometimes independent.
• Mood and emotional changes: Increased anxiety, irritability, low mood, or more significant depression. Hormonal fluctuations contribute, as do sleep loss and life stress.
• Cognitive changes (brain fog): Word‑finding difficulties, memory lapses, reduced concentration. Usually mild and transient.
• Genitourinary syndrome of menopause: Vaginal dryness, irritation, painful intercourse, urinary urgency, recurrent UTIs. These tend to persist or worsen without treatment.
• Joint and muscle symptoms: New or worsening joint stiffness and aches.
• Libido and sexual function changes: Decreased desire, reduced sensitivity, slower arousal.

Approaches to Symptom Management

Several approaches exist, often used in combination:

• Lifestyle approaches: Regular exercise, sleep hygiene, stress management, cooling strategies, pelvic floor physiotherapy.
• Non‑hormonal prescription medications: Certain antidepressants and other drugs have evidence for managing vasomotor symptoms.
• Hormone replacement therapy (HRT): Considered the most effective treatment for vasomotor symptoms and for genitourinary syndrome. Options include Health Canada–approved products and, for specific clinical needs, compounded preparations.
• Non‑prescription approaches: Some women try herbal remedies or supplements — evidence varies; discuss with your prescriber.

When Hormone Therapy Is Considered

Hormone replacement is typically considered when:

• Vasomotor symptoms are significantly affecting quality of life or sleep
• Genitourinary symptoms are present and not adequately addressed by non‑hormonal approaches
• The patient has premature or early menopause
• Other approaches have been tried and not provided sufficient relief

Risk Considerations for Hormone Therapy

Hormone therapy has potential benefits and potential risks. Among the considerations:

• Venous thromboembolism (VTE): A small increased risk has been associated with some forms of hormone therapy, particularly oral hormones. Transdermal appears to carry less risk.
• Stroke: A small increased risk, especially in older women starting therapy late after menopause.
• Breast cancer: Combined estrogen‑progestogen therapy has been associated with a small increased risk with longer use.
• Endometrial cancer: Estrogen‑only therapy in women with an intact uterus increases risk, which is why a progesterone component is added.

The "timing hypothesis" — starting near menopause has a different risk‑benefit profile than starting years later — has shaped current clinical thinking. Your prescriber considers personal and family history, age, time since menopause, and hormone formulation.

Where Compounded Hormone Therapy Fits

For most women, a Health Canada–approved product is the typical starting point. Compounded preparations are considered when an approved product cannot meet a specific clinical need: documented sensitivities, doses not available commercially, specific combinations, or a discontinued product. If your prescriber recommends compounded hormone therapy, our pharmacy is a specialist resource for formulation. If they recommend an approved product, that's the appropriate path.

What to Discuss With Your Prescriber

Useful questions to bring to your appointment:

• Which of my symptoms are most likely related to hormone changes?
• What's my personal and family history that affects hormone therapy risk?
• Should we try non‑hormonal approaches first?
• If hormone therapy makes sense, what type — approved product or compounded?
• How long would I expect to be on therapy?